Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004 Jul 1;10(13):1989-91.
doi: 10.3748/wjg.v10.i13.1989.

Enhanced antitumor efficacy on hepatoma-bearing rats with adriamycin-loaded nanoparticles administered into hepatic artery

Jiang-Hao Chen  1 , Rui Ling, Qing Yao, Ling Wang, Zhong Ma, Yu Li, Zhe Wang, Hu Xu
Affiliations

Enhanced antitumor efficacy on hepatoma-bearing rats with adriamycin-loaded nanoparticles administered into hepatic artery

Jiang-Hao Chen et al. World J Gastroenterol. .

Abstract

Aim: To investigate the antitumor activity of adriamycin (ADR) encapsulated in nanoparticles (NADR) and injected into the hepatic artery of hepatoma-bearing rats.

Methods: NADR was prepared by the interfacial polymerization method. Walker-256 carcinosarcomas were surgically implanted into the left liver lobes of 60 male Wistar rats, which were divided into 4 groups at random (15 rats per group). On the 7th day after implantation, normal saline (NS), free ADR (FADR), NADR, or ADR mixed with unloaded nanoparticles (ADR+NP) was respectively injected via the hepatic artery (i.a.) of rats in different groups. The dose of ADR in each formulation was 2.0 mg/kg body weight and the concentration was 1.0 mg/mL. Survival time, tumor enlargement ratio, and tumor necrosis degree were compared between each group.

Results: Compared with the rats that received NS i.a., the rats that received FADR or ADR+NP acquired apparent inhibition on tumor growth, as well as prolonged their life span. Further significant anticancer efficacy was observed in rats that received i.a. administration of NADR. Statistics indicated that NADR brought on a more significant tumor inhibition and more extensive tumor necrosis, as compared to FADR or ADR+NP. The mean tumor enlargement ratio on the 7th day after NADR i.a. was 1.106. The mean tumor-bearing survival time was 39.50 days. Prolonged life span ratio was 109.22% as compared with rats that accepted NS.

Conclusion: Therapeutic effect of ADR on liver malignancy can be significantly enhanced by its nanopaticle formulation and administration via hepatic artery.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Ridge JA, Collin C, Bading JR, Hancock C, Conti PS, Daly JM, Raaf JH. Increased adriamycin levels in hepatic implants of rabbit Vx-2 carcinoma from regional infusion. Cancer Res. 1988;48:4584–4587. - PubMed
    1. Eksborg S, Cedermark BJ, Strandler HS. Intrahepatic and intravenous administration of adriamycin--a comparative pharmacokinetic study in patients with malignant liver tumours. Med Oncol Tumor Pharmacother. 1985;2:47–54. - PubMed
    1. Chiannilkulchai N, Ammoury N, Caillou B, Devissaguet JP, Couvreur P. Hepatic tissue distribution of doxorubicin-loaded nanoparticles after i.v. administration in reticulosarcoma M 5076 metastasis-bearing mice. Cancer Chemother Pharmacol. 1990;26:122–126. - PubMed
    1. Andrieu V, Fessi H, Dubrasquet M, Devissaguet JP, Puisieux F, Benita S. Pharmacokinetic evaluation of indomethacin nanocapsules. Drug Des Deliv. 1989;4:295–302. - PubMed
    1. Zou YY, Ueno M, Yamagishi M, Horikoshi I, Yamashita I, Tazawa K, Gu XQ. Targeting behavior of hepatic artery injected temperature sensitive liposomal adriamycin on tumor-bearing rats. Sel Cancer Ther. 1990;6:119–127. - PubMed

MeSH terms